Lexeo Therapeutics will announce its third quarter 2026 financial results and provide a business update on November 16, focusing on the progress of its LX2020 gene therapy for PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). LX2020 is an AAV-based gene therapy targeting the genetic cause of this heart condition, which affects about 60,000 people in the U.S. The therapy is currently in a Phase I/II clinical trial and has received several FDA designations to expedite its development. Investors and analysts can join a webcast for more details, with a replay available afterward.
Lexeo Therapeutics' upcoming third quarter 2026 financial results and business update provide context for health sector investors. Of 150 priced US health stocks on Pluang, 71 rose and 77 fell today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.31 with a 6.14% decline, Summit Therapeutics Inc (SMMT) at USD 14.15 down 6.14%, and Ginkgo Bioworks Holdings Inc (DNA) at USD 9.61 down 6.06%, as of Nov 15, 2026 17:31 WIB.
At the 2026 Chery International User Summit, Chery introduced a new integrated travel ecosystem combining autonomous Robotaxi, electric vertical takeoff and landing (eVTOL) aircraft, and advanced smart valet parking. This system aims to connect land ...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem combining a Level 4 Robotaxi, eVTOL aircraft models Lingxiao Q212 and J506, and a Super Intelligent Valet Parking system. This integrated approach aims to ov...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, two eVTOL aircraft models, and a Super Intelligent Valet Parking system. This integrated approach aims to reduce modal transfer...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, eVTOL aircraft Lingxiao models, and Super Intelligent Valet Parking (SIVP). This system aims to seamlessly integrate land and a...
Lumentum Holdings reported a strong Q1 with revenue up 136.5% year-over-year to $1.26 billion and adjusted operating margins expanding to 42.3%. The company saw a 228.8% increase in systems revenue and generated over $108 million from optical switchi...
